

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PREScriBER

Name: Name:

Ward: NHI:

Epoetin alfa

INITIATION – chronic renal failure

Prerequisites (tick boxes where appropriate)

- Patient in chronic renal failure
- and
- Haemoglobin is less than or equal to 100g/L
- and
- Patient does not have diabetes mellitus
- and
- Glomerular filtration rate is less than or equal to 30ml/min
- or
- Patient has diabetes mellitus
- and
- Glomerular filtration rate is less than or equal to 45ml/min
- or
- Patient is on haemodialysis or peritoneal dialysis

INITIATION – myelodysplasia*

Re-assessment required after 2 months

Prerequisites (tick boxes where appropriate)

- Patient has a confirmed diagnosis of myelodysplasia (MDS)
- and
- Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent
- and
- Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS)
- and
- Other causes of anaemia such as B12 and folate deficiency have been excluded
- and
- Patient has a serum epoetin level of < 500 IU/L
- and
- The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week

CONTINUATION – myelodysplasia*

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The patient's transfusion requirement continues to be reduced with epoetin treatment
- and
- Transformation to acute myeloid leukaemia has not occurred
- and
- The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward: NHI:

Epoetin alfa - continued

INITIATION – all other indications

Prerequisites (tick box where appropriate)

Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.
and
 For use in patients where blood transfusion is not a viable treatment alternative

Note: Indications marked with * are unapproved indications

I confirm that the above details are correct:

Signed: Date: